Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.61 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.60 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | OSBP | P22059 | 1/20 | 0.56 |
| ▸ | RORC | P51449 | 1/20 | 0.56 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.56 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | GBA1 | P04062 | 2/20 | 0.51 |
| ▸ | UGCG | Q16739 | 2/20 | 0.51 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.51 |
| ▸ | NPC1L1 | Q9UHC9 | 3/20 | 0.51 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949176 | 1.00 | POLA1 (0.61) | POLA1CYP46A1PLA2G2AUSP2LMNA | |
| SCHEMBL3155816 | 1.00 | POLA1 (0.61) | POLA1CYP46A1PLA2G2AUSP2LMNA | |
| SCHEMBL318236 | 1.00 | POLA1 (0.61) | POLA1CYP46A1PLA2G2AUSP2LMNA | |
| SCHEMBL3155812 | 1.00 | POLA1 (0.61) | POLA1CYP46A1PLA2G2AUSP2LMNA | |
| SCHEMBL9949178 | 1.00 | POLA1 (0.61) | POLA1CYP46A1PLA2G2AUSP2LMNA | |
| SCHEMBL318235 | 1.00 | POLA1 (0.61) | POLA1CYP46A1PLA2G2AUSP2LMNA | |
| SCHEMBL15025486 | 0.99 | POLA1 (0.62) | POLA1CYP46A1PLA2G2AUSP2LMNA | |
| SCHEMBL17244044 | 0.94 | POLA1 (0.62) | POLA1CYP46A1PLA2G2AUSP2LMNA | |
| SCHEMBL17243858 | 0.92 | POLA1 (0.59) | POLA1CYP46A1PLA2G2AUSP2LMNA | |
| SCHEMBL20411514 | 0.92 | POLA1 (0.68) | POLA1CYP46A1USP2LMNAABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205283-B1 | CHOLESTEROL CONJUGATES OF INHIBITORS OF VIRAL FUSION | MSD ITALIA SRL (IT) | 2019-03-20 | — | — | EP | disclosed |
| US-8629101-B2 | Cholesterol derivatives of inhibitors of viral fusion | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2014-01-14 | — | — | US | disclosed |
| US-8629101-B2 | Cholesterol derivatives of inhibitors of viral fusion | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2014-01-14 | — | — | US | disclosed |
| US-20130196903-A1 | Multimeric Inhibitors of Viral Fusion and Uses Thereof | JV BIO SRL (IT) | 2013-08-01 | — | — | US | disclosed |
| US-20130196903-A1 | Multimeric Inhibitors of Viral Fusion and Uses Thereof | JV BIO SRL (IT) | 2013-08-01 | — | — | US | disclosed |
| US-20130150563-A1 | LIPID-CONJUGATED ANTIBODIES | JV BIO SRL (IT) | 2013-06-13 | — | — | US | disclosed |
| US-20130150563-A1 | LIPID-CONJUGATED ANTIBODIES | JV BIO SRL (IT) | 2013-06-13 | — | — | US | disclosed |
| US-20100305028-A1 | CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION | MSD ITALIA S.R.L. (IT) | 2010-12-02 | — | — | US | disclosed |
| WO-2010089129-A1 | INHIBITORS OF VIRAL FUSION AND USES THEREOF | CORMUS SRL (IT) | 2010-08-12 | — | — | WO | disclosed |
| WO-2009053339-A2 | CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150563-A1 | LIPID-CONJUGATED ANTIBODIES | GPR119, FCGR1A, LIPG | POLA1 3845/4885CYP46A1 10/4885PLA2G2A 511/4885 |
| US-20100305028-A1 | CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION | HDLBP, CETP, NPC1 | POLA1 3439/4885CYP46A1 10/4885PLA2G2A 809/4885 |
| US-20130196903-A1 | Multimeric Inhibitors of Viral Fusion and Uses Thereof | HAVCR2, ZC3HAV1, BST2 | POLA1 4407/4885CYP46A1 3039/4885PLA2G2A 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.